ANAVEX LIFE SCIENCES CORP.
630 5th Avenue, 20th Floor
New York, NY USA 10111
July 21, 2025
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Jessica Dickerson
| Re: | Anavex Life Sciences Corp. | |
| Request for Acceleration of Registration Statement on Form S-3 | ||
| File No. 333-288661 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anavex Life Sciences Corp., a Nevada corporation (the “Company”), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3 (File No. 333-288661), filed with the U.S. Securities and Exchange Commission on July 14, 2025, to 4:00 P.M. ET on July 23, 2025 or as soon thereafter as practicable.
Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 or Clayton.Parker@klgates.com of K&L Gates LLP, legal counsel to the Company.
| Sincerely, | |
| /s/ Christopher Missling, PhD | |
| Christopher Missling, PhD Chief Executive Officer |